Sequana Medical NV (FRA:2SE) Long-Term Debt: €0.00 Mil (As of Jun. 2025)


FRA:2SE Sequana Medical NV FRA:2SE
31 GF Score
Price €0.51
GF Value €0.19
! 12 Warning Signs
View Full Analysis

What is Sequana Medical NV Long-Term Debt?

Sequana Medical NV FRA:2SE 31 Long-Term Debt is €0.00 Mil as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review.

Sequana Medical NV's Long-Term Debt for the quarter that ended in Jun. 2025 was €0.00 Mil.

Sequana Medical NV's quarterly Long-Term Debt declined from Jun. 2024 (€11.87 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil).

Sequana Medical NV's annual Long-Term Debt declined from Dec. 2022 (€12.19 Mil) to Dec. 2023 (€8.97 Mil) and declined from Dec. 2023 (€8.97 Mil) to Dec. 2024 (€0.00 Mil).

Sequana Medical NV  (FRA:2SE) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sequana Medical NV Long-Term Debt Related Terms

Sequana Medical NV Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sequana Medical NV's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sequana Medical NV Long-Term Debt Chart

Sequana Medical NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.47 7.33 12.19 8.97 0.00

Sequana Medical NV Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.91 8.97 11.87 0.00 0.00
FRA:2SE
31GF Score
Sequana Medical NV FRA:2SE
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Sequana Medical NV (FRA:2SE) has a Long-Term Debt of €0.00 Mil as of Jun. 2025.
Is Sequana Medical NV's Long-Term Debt too high?
Sequana Medical NV's current Long-Term Debt is €0.00 Mil. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Long-Term Debt compare to ABT and SYK?
Sequana Medical NV's Long-Term Debt of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sequana Medical NV's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Long-Term Debt of €0.00 Mil. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Long-Term Debt is €0.00 Mil. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Long-Term Debt is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?

Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued. The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.

Key valuation signals for FRA:2SE:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
  • GF Score™: 31/100 with 12 warning signs

No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sequana Medical NV Business Description

Other Exchanges 2SE:GermanySEQUA:Belgium
Address Kortrijksesteenweg 1112, bus 102, Sint-Denijs-Westrem, Ghent, BEL, 9051
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score

Get the complete analysis for FRA:2SE

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.19
GF Value